ქებაჲ და დიდებაჲ ქართულისა ენისაჲ

წმინდათა ცხოვრებანი 981 წ. 223 v (მთავრულით) ქართოჳლისა ენისა თჳს დამარხულარს ენაჲ ქართოჳლი დღემდე მეორედ მოსლვისა მისისა საწამებელად რა ყლსა ენასა ღნ ამხილოს ამით ენითა და ესე ენაჲ მძინარე არს დღესა მომდე და სახარებასა შინა ამას ენასა ლაზარე ჰქჳან და ახალმან ნინო მოაქცია და ელენე დედოჳფალმან [...] არიან ორნი დანი ვა მრმ და მართაჲ და მეგობრობაჲ ამის თჳს ღქა ვდ ყლი საჲდოჳმლოჲ ამას ენასა შინა დამარხულარს და ოთხისა დღისა მკოჳდარი ამის თჳს თქა დთ წწტყლმნ რ წელი ათასი ვა ერთი დღჱ და სახარებასა შინა ქართოჳლსა თავსა ხ მათესსა წერილი ზის რლ ასოჲ არს და იტყჳს ოთხ ათასსა მარაგსა და ესე არს ოთხი დღჱ და ოთხისა დღისა მკოჳდარი ამის თჳს მისთანა დაფლოჳლი სიკოჳდილითა ნათლის ღებისა მისისაჲთა და ესე ენაჲ შემკოჳლი და კხლი სახელითა ღჲთა მდაბალი და დაწოჳნებუოჳლი მოელის დღესა მას მეორედ მოსლვასა ოისასა და სასწაოჳლად ესე აქოჳს ოთხმეოც და ათოთხმეტნი წელი ოჳმეტეს სხოჳათა ენათა ქეს მოსლვით გნ ვე დღესა მომდე და ესე ყლი რლი წერილ არს მოწამედ წარმოგითხრას ესე წილი ანბანისაჲ. ლც ყვთ

[იყვ]ნეს ცოდვილ რ ესევითარნი ევნო მათ]

I-II+1r-144v 3 წიგნი; I წიგნი 1r-50v Inc. იყვ]ნეს ცოდვილ რ ესევითარნი ევნო მათ Des. რ სიყარლი ღთისაჲ არა გაქოჳს თავისა თქენისა თანა; II წიგნი 51r-100v Inc. მე მოვედ სახელითა მამისა ჩემისაჲთა Des. (98v) ლცსა თქნსა გვედიეთ და ყლი დაკლბბაჲ და ოÂგნბჲ ჩმი შემდთ და თქნსა ქნ შგწყნ ან (ნუსხურით); III წიგნი 101r-144v Inc. განგებაჲ და განწესებაჲ წთა სახარებათაჲ წელიწდისა დღეთაჲ და დღესასწაოÂლთაჲ Des. მხტნისა ბაცილასა (sic) ანადარნი–ცაესა (sic) მისასამე აღალესა მაჭაუტა ჶახესა (?) ღმერთმნა შაუდს, ამნ; ნაკლულია, აკლია დასაწყისის 21 რვეული, 22–დან შემორჩენილია 6 ფურცელი. 68–ე ფურცელზე მარკოზ მოციქულის გამოსახულება, მე–100 ფურცელზე – მათეს გამოსახულება. ორივეს აქვს ქართული წარწერა. როგორც ჩანს, ხატები სხვა ხელნაწერის კუთვნილებაა. აქვს მუხლების და პარალელური ადგილების მაჩვენებლები. 146v ბერძნული პალიმფსესტია, 99r, 99v არ იკითხება.

Nutrição mineral de hortaliças: LXXV. absorção de nutrientes pela cultura de almeirão

De uma plantação de almeirão (Chicorium intybus c.v. Folha Larga) foram coletadas 30 plantas com 4 repetições aos 25, 35, 45 e 55 dias após a emergência. O material coletado foi dividido em folhas e raízes e analisados por N, P, K, Ca, Mg, S, B, Cu, Fe, Mn, Zn, pelos métodos convencionais de laboratório. O elemento extraído em maior quantidade foi o nitrogênio, seguido de potássio, cálcio, fósforo, magnésio e enxofre. Dentre os micronutrientes o elemento extraído em maiores quantidades foi o ferro, seguido do manganês, zinco, boro e finalmente pelo cobre. Estabelece-se o nível crítico para os nutrientes os seguintes valores: 4,39% N, 0,47% P, 2,93 K, 1,00 % Ca, 0,35% Mg, 0,20% S, 59 ppm B, 15 ppm Cu, 2,926 ppm Fe, 117 ppm Mn e 80 ppm Zn. A extração total por folhas e raízes foi de 5.000 plantas/100 m² e de 92,3 g N, 13,3 g P, 83,2 g K, 28,8 g Ca, 8,6 g Mg, 5,45 g S, 154 mg B, 38 mg Cu, 7,979 mg Fe, 301 mg Mn e 214 mg Zn.

Long-Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatment-Experienced Patients in Switzerland.

Background. Accurate quantification of the prevalence of human immunodeficiency virus type 1 (HIV-1) drug resistance in patients who are receiving antiretroviral therapy (ART) is difficult, and results from previous studies vary. We attempted to assess the prevalence and dynamics of resistance in a highly representative patient cohort from Switzerland. Methods. On the basis of genotypic resistance test results and clinical data, we grouped patients according to their risk of harboring resistant viruses. Estimates of resistance prevalence were calculated on the basis of either the proportion of individuals with a virologic failure or confirmed drug resistance (lower estimate) or the frequency-weighted average of risk group-specific probabilities for the presence of drug resistance mutations (upper estimate). Results. Lower and upper estimates of drug resistance prevalence in 8064 ART-exposed patients were 50% and 57% in 1999 and 37% and 45% in 2007, respectively. This decrease was driven by 2 mechanisms: loss to follow-up or death of high-risk patients exposed to mono- or dual-nucleoside reverse-transcriptase inhibitor therapy (lower estimates range from 72% to 75%) and continued enrollment of low-risk patients who were taking combination ART containing boosted protease inhibitors or nonnucleoside reverse-transcriptase inhibitors as first-line therapy (lower estimates range from 7% to 12%). A subset of 4184 participants (52%) had 1 study visit per year during 2002-2007. In this subset, lower and upper estimates increased from 45% to 49% and from 52% to 55%, respectively. Yearly increases in prevalence were becoming smaller in later years. Conclusions. Contrary to earlier predictions, in situations of free access to drugs, close monitoring, and rapid introduction of new potent therapies, the emergence of drug-resistant viruses can be minimized at the population level. Moreover, this study demonstrates the necessity of interpreting time trends in the context of evolving cohort populations.

El ensayo inmunoenzimatico en microgotas sobre nitrocelulosa (Dot-ELISA) en el diagnostico de la enfermedad de Chagas: I. Estudio comparativo de dos preparaciones antigenicos de Trypanosoma cruzi

Se estudia el Ensayo Inmunoenzimático en Microgotas sobre Nitrocelulosa (Dot-ELISA)comparando dos preparados antigénicos de formas epimastigotas de cultivo de T. cruzi: 1) la fracción citoplasmática (antígeno citoplasmático y 2) el parásito total fijado previamente con formaldehido (antígeno integral). Se usaron sueros de: 95 pacientes chagásicos con serología convencional positiva, cardiopatía crónica y algunos con xenodiagnóstico positivo; 42 personas sanas y 32 con miocardipatía crónica con serología negativa y 74 pacientes con diferentes patologías incluyendo: sífilis, toxoplasmosis, lupus eritematoso diseminado, con factor reumatoide, leishmaniasis visceral, y leishmaniasis cutánea. Definidos los títulos diagnósticos (cut-off) de 1:512 con antígeno citoplasmático y de 1: 128 con antígeno integral, la especificidad fue 96% para el primero y de 100% para el segundo; mientras que la sensibilidad fue de 100% para ambas. En el estudio comparativo con las pruebas serológicas convencionales examinando 147 sueros tomados de personas referidas al laboratório, Dot-ELISA con antígeno citoplasmático presentó índices deco-positividad de 1,0, co-negatividad de 0,989 y eficiencia 0,993. Dot-ELIS con antígeno integral dió 1,0, 0,979 y 0,986 respectivamente. De acuerdo con esta evaluación, la técnica Dot-ELISA con antígeno integral se presenta como una alternativa práctica para el diagnóstico serológico de la enfermedad de Chagas.

Plasma Level of Mmp-9 as Predictive Factor for Response and Progression Free Survival in Patients Treated with Bevacizumab (Bev) and Pegylated Liposomal Doxorubicin (Pld): Sakk 24/06

Background: There is currently no identified marker predicting benefit from Bev in patients with breast cancer (pts). We monitored prospectively 6 angiogenesis-related factors in the blood of advanced stage pts treated with a combination of Bev and PLD in a phase II trial of the Swiss Group for Clinical Cancer Research, SAKK.Methods: Pts received PLD (20 mg/m2) and Bev (10 mg/kg) every 2 weeks for a maximum of 12 administrations, followed by Bev monotherapy until progression or severe toxicity. Blood samples were collected at baseline, during treatment and at treatment discontinuation. Enzyme-linked immunosorbent assays (Quantikine, R&DSystems and Reliatech) were used to measure vascular endothelial growth factor (VEGF), placental growth factor (PlGF), matrix metalloproteinase 9 (MMP-9) and soluble VEGF receptors -1, -2 and -3. The natural log-transformed (ln) data for each factor was analyzed by analysis of variance (ANOVA) model to investigate differences between the mean values of the subgroups of interest (where a = 0.05), based on the best tumor response by RECIST.Results: 132 samples were collected in 41 pts. The mean of baseline ln MMP-9 levels was significantly lower in pts with tumor progression than those with tumor response (p=0.0202, log fold change=0.8786) or disease control (p=0.0035, log fold change=0.8427). Higher MMP-9 level was a significant predictor of superior progression free survival (PFS): p=0.0417, hazard ratio=0.574, 95% CI=0.336-0.979. In a multivariate cox proportional hazards model, containing performance status, disease free interval, number of tumor sites, visceral involvement and prior adjuvant chemotherapy, using stepwise regression baseline MMP-9 was still a statistically 117P Table 1. SOLTI-0701* AC01B07* NU07B1* SOR+CAP N=20 PL+CAP N=33 SOR+ GEM/CAP N=23 PL+ GEM/CAP N=27 SOR+PAC N=48 PL+PAC N=46 Baseline characteristics Age, median (range), y 49 (32-72) 53 (30-78 54 (32-69) 57 (31-82) 50 (27-80) 52 (23-74) AJCC stage, n (%) IIIB/IIIC 3 (15) 6 (18) 0 (0) 3 (11) 8 (17) 9 (20) IV 17 (85) 27 (82) 23 (100) 24 (89) 40 (83) 37 (80) Metastatic site, n (%) Non-visceral 3 (15) 6 (18) 7 (30) 6 (22) 9 (19) 17 (37) Visceral 17 (85) 27 (82) 16 (70) 21 (78) 39 (81) 29 (63) Prior metastatic chemo, n (%) 8 (40) 15 (45) 21 (91) 25 (93) - - Efficacy PFS, median, mo 4.3 2.5 3.1 2.6 5.6 5.5 HR (95% CI)_ 0.60 (0.31, 1.14) 0.57 (0.30, 1.09) 0.86 (0.50, 1.45) 1-sided P value_ 0.055 0.044 0.281 Overall survival, median, mo 17.5 16.1 Pending 14.7 18.2 HR (95% CI)_ 0.98 (0.50, 1.89) 1.11 (0.64, 1.94) 1-sided P value_ 0.476 0.352 Safety N=20 N=33 N=22 N=27 N=46 N=46 Tx-emergent Grade 3/4, n (%) 15 (75) 16 (48) 20 (91) 17 (63) 36 (78) 16 (35) Grade 3§ hand-foot skin reaction/ syndrome 8 (40) 5 (15) 8 (36) 0 (0) 14 (30) 2 (4) *Efficacy results based on intent-to-treat population and safety results based on safety population (pts who received study drug[s]); _Cox regression within each subgroup; _log-rank test within each subgroup; §maximum toxicity grade for hand-foot skin reaction/syndrome; AJCC, American Joint Committee on Cancer mittedabstractsª The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com Downloaded from annonc.oxfordjournals.org at Bibliotheque Cantonale et Universitaire on June 6, 2011 significant factor (p=0.0266). The results of the other measured factors were presented elsewhere.Conclusions: Higher levels of MMP-9 could predict tumor response and superior PFSin pts treated with a combination of Bev and PLD. These exploratory results justify further investigations of MMP-9 in pts treated with Bev combinations in order to assess its role as a prognostic and predictive factor.Disclosure: K. Zaman: Participation in advisory board of Roche; partial sponsoring ofthe study by Roche (the main sponsor was the Swiss Federation against Cancer (Oncosuisse)). B. Thu¨rlimann: stock of Roche; Research grants from Roche. R. vonMoos: Participant of Advisory Board and Speaker honoraria

The eta invariant and equivariant index of transversally elliptic operators

We prove a formula for the multiplicities of the index of an equivariant transversally elliptic operator on a G-manifold. The formula is a sum of integrals over blowups of the strata of the group action and also involves eta invariants of associated elliptic operators. Among the applications, we obtain an index formula for basic Dirac operators on Riemannian foliations, a problem that was open for many years.

2006 Drugs estimate refuels debate on governance, Issue 17, Spring 2006

In November 2005 €34.027 million was voted for the Drugs Initiative, which funds the local and regional drugs task forces, and the Young People’s Facilities and Services Fund (YPFSF), in 2006 – an 8 per cent increase on the allocation for 2005 and ‘well in excess of inflation’ according to the government. The community sector strongly criticised this estimate, calling for an additional €8 million to €15 million, to fund the projects identified following the creation of the Emerging Needs Fund in January 2005. In February 2006, the government revised its drugs estimate upwards by a further €8.979 million. As well as criticising the 2006 drugs estimate, the community sector raised a series of concerns with regard to governance – the rules, processes and behaviour that affect the way in which powers are exercised4 – or, in short, decision-making with regard to drugs policy in Ireland.This resource was contributed by The National Documentation Centre on Drug Use.

Anàlisi, disseny i implementació d'una botiga virtual amb tecnologia J2EE

Aquest treball final de carrera té com a finalitat aprofundir en el coneixement de les plataformes tecnològiques que permeten el desenvolupament de solucions e-business, i conèixer el negoci del comerç electrònic, en aquest TFC es proposa desenvolupar una aplicació de comerç electrònic usant tecnologia J2EE.

Variabilité intra/interobservateur du coefficient de diffusion apparente dans les lésions hépatiques malignes traitées

Objectifs : Le coefficient de diffusion apparente (ADC) est utilisé pour le suivi des lésions hépatiques malignes traitées. Cependant, l'ADC est généralement mesuré dans la lésion entière, alors que cela devrait être réalisé dans la zone la plus restreinte (ZLPR), cette dernière représentant potentiellement du résidu tumoral. Notre objectif était d'évaluer la variabilité inter/intraobservateur de l'ADC dans la tumeur entière et dans la ZLPR. Matériels et méthodes : Quarante patients traités par chimioembolisation ou radiofréquence ont été évalués. Après consensus, deux lecteurs ont indépendamment mesuré l'ADC de la lésion entière et de la ZLPR. Les mêmes mesures ont été répétées deux semaines plus tard. Le test de Spearman et la méthode de Bland-Altman ont été utilisées. Résultats : La corrélation interobservateur de l'ADC dans la lésion entière et dans la ZLPR était de 0,962 et de 0,884. La corrélation intraobservateur était de 0,992 et de 0,979, respectivement. Les limites de variabilité interobservateur (mm2/sec*10 - 3) étaient entre -0,25/+0,28 dans la lésion entière et entre -0,51/+0,46 dans la ZLPR. Les limites de variabilité intraobservateur étaient respectivement : -0,25/+0,24 et -0,43/+0,47. Conclusion : La corrélation inter/intraobservateur dans les mesures d'ADC est bonne. Toutefois, une variabilité limitée existe et doit être considérée lors de l'interprétation des valeurs d'ADC des tumeurs hépatiques.

The high road and the low road: trafficking choices in plants.

Polar transport of the signaling molecule auxin is critical for plant development and depends on both the polar distribution of auxin efflux carriers, which pump auxin out of the cell and the alignment of these polarized cells. Two papers in this issue of Cell (Michniewicz et al., 2007; Jaillais et al., 2007) address how polar transport of these carriers occurs and describe the endosomal pathways involved.